论文部分内容阅读
为了探讨吉西他滨+顺铂方案治疗中晚期食管癌的疗效及预后,对56例中晚期食管癌患者行吉西他滨+顺铂方案化疗,观察治疗前后影像学变化,全身、饮食状况,给予手术治疗或放疗。化疗后手术组18例,2例行颈部吻合,6例行食管胃弓上吻合,9例行食管胃弓下吻合术,1例行开胸探查术。开胸探查1例,患者术后未行综合治疗,生存期半年;颈部吻合1例,术后未行规范化治疗,生存期14个月;未行手术治疗组38例,中位生存时间13个月。初步研究结果提示,化疗后部分患者病变明显缩小,和周围脏器、组织、大血管边界变清晰,从而获得手术机会;未能手术治疗组患者全身、饮食状况改善。患者耐受性好,该化疗方案值得临床广泛推广应用。
To investigate the efficacy and prognosis of gemcitabine + cisplatin in the treatment of advanced esophageal cancer, 56 cases of advanced esophageal cancer patients underwent gemcitabine plus cisplatin regimen chemotherapy before and after imaging changes, systemic, diet, surgery or radiotherapy . There were 18 cases in the operation group after chemotherapy, 2 cases underwent neck anastomosis, 6 cases underwent esophagogastric anastomosis, 9 under esophagogastric arch anastomosis and 1 case underwent thoracotomy. Thoracotomy exploration in 1 case, patients without comprehensive treatment, survival of six months; neck anastomosis, postoperative standardized treatment, the survival period of 14 months; no surgical treatment group of 38 patients, the median survival time 13 Months. Preliminary results suggest that some patients after chemotherapy significantly reduced pathological changes, and surrounding organs, tissues, large blood vessel boundaries become clear, so as to obtain surgical opportunities; failed surgery group patients with systemic, improved diet. Patients are well tolerated, the chemotherapy program deserves widespread clinical application.